Understanding Inappropriate Shocks in Subcutaneous and Transvenous ICDs

Implantable cardioverter-defibrillators (ICDs) are highly effective at terminating life-threatening ventricular tachycardia (VT) and ventricular fibrillation (VF). A shock delivered for atrial fibrillation, supraventricular tachycardia, oversensing, or a device or lead problem is different: it is an inappropriate shock. Although these therapies may prevent sudden cardiac death in the right circumstances, inappropriate shocks can cause pain, anxiety, myocardial injury, reduced quality of life, and avoidable hospital presentations.

The choice between a subcutaneous ICD (S-ICD) and a transvenous ICD (TV-ICD) influences the mechanisms, frequency, and management of inappropriate therapy. Both systems depend on reliable rhythm discrimination and carefully tailored programming. Understanding their distinct sensing architectures helps clinicians interpret stored electrograms, counsel patients, and reduce preventable shocks across Australian practice settings.

How the Two Systems Sense Rhythm

A TV-ICD uses one or more intracardiac leads positioned in the right ventricle, with sensing electrodes close to the myocardium. It can analyse ventricular electrograms and, in dual-chamber systems, atrial activity as well. This permits discrimination between ventricular arrhythmia and some supraventricular rhythms, including atrial fibrillation, atrial flutter, and sinus tachycardia. The lead can also provide antitachycardia pacing (ATP), which may terminate monomorphic VT without a shock.

An S-ICD places the pulse generator laterally near the left axilla and the electrode subcutaneously along the sternum. It does not enter the heart or vasculature, and it generally has no atrial channel or ATP function. Rhythm detection relies on sensing vectors across the thorax, so signal quality is affected by body position, posture, exercise, cardiac morphology, and changes in the relationship between the generator and electrode. The system’s major procedural advantage is also the source of a different sensing profile.

Common Triggers for Inappropriate Therapy

In TV-ICDs, rapid atrial arrhythmias are a frequent cause of inappropriate shocks. Atrial fibrillation with a fast ventricular response can enter the programmed therapy zone, particularly when rate cut-offs are low or detection intervals are short. Sinus tachycardia during exertion may create a similar problem in younger or physically active patients. Discrimination algorithms can reduce this risk, but they are not infallible, especially when ventricular rates are very rapid or electrograms are complex.

Lead-related problems are another important cause. Conductor fracture, insulation failure, connector issues, or intermittent contact can generate non-physiological signals that mimic ventricular fibrillation. T-wave oversensing may cause the device to count repolarisation as additional ventricular events. Myopotential oversensing and electromagnetic interference are less common but clinically relevant. A sudden cluster of shocks, especially in a stable patient, should prompt urgent assessment for lead noise or another hardware problem.

S-ICDs avoid intravascular lead failure but have their own sources of inappropriate detection. T-wave oversensing is particularly important because the device senses a subcutaneous far-field signal rather than a local intracardiac ventricular electrogram. Low-amplitude QRS complexes, prominent T waves, changes caused by exercise, and shifts in body position can alter the QRS-to-T-wave relationship. External electrical noise and myopotential signals may also be misclassified as ventricular arrhythmia. Screening and vector selection reduce, but do not eliminate, these events.

Why Inappropriate Shocks Matter

An inappropriate shock is physically distressing and can reinforce fear of device therapy. Patients may avoid exercise, sleep poorly, or become reluctant to travel far from medical care. Recurrent shocks may lead to emergency presentations, driving restrictions, psychological morbidity, and reduced trust in the device. In Australia, a patient living in regional New South Wales, Western Australia, or northern Queensland may also face long travel times to an electrophysiology service after a single event.

Repeated shocks can increase sympathetic activation and may provoke myocardial injury. They can also trigger a cycle in which anxiety raises heart rate, a faster rhythm enters the therapy zone, and the resulting shock further heightens distress. For patients with inherited arrhythmia syndromes or structural heart disease, clinicians should assess whether an apparently inappropriate episode might have been preceded by a genuine ventricular arrhythmia or electrical instability.

The response should therefore be proportionate but prompt. Patients should receive clear instructions about when to call emergency services, particularly after multiple shocks, syncope, chest pain, or persistent palpitations. A single shock in a stable patient still warrants device interrogation and clinical review, rather than reassurance based only on symptom resolution.

Comparing Risk Profiles

Neither device category has a universal advantage for every patient. S-ICDs avoid venous obstruction, pneumothorax from a transvenous lead, lead extraction risk, and infection involving an intracardiac lead. This can be valuable in younger patients expected to need decades of device therapy, people with limited venous access, and those at increased risk of bloodstream infection. It is also attractive when pacing is not required.

TV-ICDs offer a broader range of rhythm-management functions. ATP can reduce the number of painful shocks for recurrent monomorphic VT, and bradycardia pacing may be essential in selected patients. Some systems provide cardiac resynchronisation therapy for heart failure. Their intracardiac sensing may provide stronger rhythm discrimination in particular clinical situations, although lead failure and atrial arrhythmia-related shocks remain important limitations.

Comparisons of inappropriate shock rates should be interpreted carefully. Outcomes depend on device generation, programming, patient age, arrhythmia substrate, follow-up duration, and definitions used in each study. Contemporary high-rate detection, longer detection intervals, morphology algorithms, remote monitoring, and improved S-ICD sensing have reduced event rates across both platforms. A headline percentage from an older trial should not substitute for individual risk assessment.

Patient Selection and Australian Practice

S-ICD candidacy requires more than an indication for sudden-death prevention. The patient must generally have no current need for bradycardia pacing, ATP, or resynchronisation, and the expected benefits of avoiding a transvenous system must outweigh the limitations of subcutaneous sensing. Pre-implant ECG screening in several vectors is central to reducing T-wave oversensing. Screening should be considered alongside the patient’s rhythm history, body habitus, cardiomyopathy, activity level, and likelihood of future pacing needs.

In hypertrophic cardiomyopathy, sudden-death risk, age, family history, ventricular arrhythmia burden, left ventricular morphology, and lifestyle all influence device selection. A focused discussion of selection criteria can help frame why an S-ICD may suit some patients while a TV-ICD is more appropriate for others. The decision should be shared with the patient and documented in terms that remain understandable during later emergency care.

Australian geography and health-system arrangements add practical considerations. Patients may receive initial assessment in a metropolitan centre such as Melbourne, Sydney, Brisbane, Perth, or Adelaide, then return to a local cardiology or general practice service. Device clinics should provide an accessible plan for remote review, wound concerns, shocks, and transfer of stored electrograms. Aboriginal and Torres Strait Islander patients and people in remote communities may require culturally safe communication and additional planning for transport and continuity of care.

Programming and Follow-Up Strategies

Programming is one of the most effective ways to reduce inappropriate therapy. Higher therapy-rate thresholds and longer detection durations can allow brief sinus tachycardia or non-sustained ventricular arrhythmia to terminate before a shock is delivered. For TV-ICDs, appropriate use of morphology, stability, and atrial-based discrimination can improve specificity. ATP before shock is useful when the clinical VT is likely to respond, although programming must reflect the patient’s arrhythmia characteristics.

S-ICD programming should include deliberate selection of the sensing vector and attention to exercise-related changes. A vector that appears satisfactory at rest may become unreliable with movement or increased heart rate. Provocative assessment, including posture and exercise when appropriate, can reveal oversensing that a standard resting ECG misses. Follow-up should revisit sensing after significant weight change, lead or generator revision, and any symptoms suggesting recurrent device interference.

Remote monitoring can identify lead noise, high-rate episodes, battery changes, and repeated detections before a patient experiences multiple shocks. Nevertheless, alerts require clear ownership and timely review. A device clinic in a busy Australian tertiary hospital should have escalation pathways for after-hours notifications, rural referrals, and patients who cannot attend promptly. Programming should be revisited after every inappropriate event rather than treating the shock as an isolated incident.

Clinical Assessment After a Shock

The first assessment includes symptoms, number and timing of shocks, posture or activity at the time, medication adherence, recent illness, electrolyte disturbance, and possible exposure to electrical interference. Patients with syncope, haemodynamic compromise, ongoing arrhythmia, or repeated shocks need urgent emergency evaluation. A 12-lead ECG, electrolytes, renal function, medication review, and assessment for myocardial ischaemia or heart failure may be appropriate depending on the presentation.

Device interrogation is essential. Clinicians should determine whether the episode was caused by atrial arrhythmia, sinus tachycardia, T-wave oversensing, lead noise, myopotential interference, or a true ventricular arrhythmia that fell outside the intended discrimination strategy. Stored electrograms should be reviewed with the clinical context; automated device labels can be misleading. For S-ICDs, comparing vectors and examining changes during posture or exertion may clarify the mechanism.

Treatment depends on the cause. Atrial fibrillation may require rate control, rhythm management, anticoagulation assessment, or ablation. A suspected lead fracture or connector problem may require reprogramming, lead revision, extraction, or system replacement. Sensing abnormalities may be addressed through vector changes or programming, but persistent oversensing can require surgical revision. Psychological support should form part of care, particularly after repeated shocks or when fear is affecting normal activity.

Reducing Future Events Through Research

The field continues to move towards more selective therapy, better signal processing, and patient-specific programming. Improvements in subcutaneous filtering and machine-learning approaches may help distinguish QRS complexes from T waves and non-cardiac noise. In TV-ICDs, advanced discrimination and remote diagnostics aim to identify lead failure earlier and reduce unnecessary therapies. These developments should be evaluated alongside clinical outcomes, not simply detection accuracy.

High-quality registries and comparative studies remain important because device performance varies across populations. Evidence from Australian and Asia-Pacific cohorts can clarify how body size, physical activity, access to specialist services, and long-distance follow-up affect outcomes. Clinicians and researchers preparing original studies, reviews, or clinical guidance can consult the journal’s submission guidance when developing work for peer review.

For trainees, the practical lesson is straightforward: an ICD shock is an event to explain, not merely a device alert to silence. Careful electrogram review, thoughtful programming, reliable follow-up, and patient education can substantially reduce recurrence. Selecting an S-ICD or TV-ICD should reflect the patient’s arrhythmia substrate, pacing needs, future clinical trajectory, and access to care.

Clinicians can apply these principles by auditing inappropriate therapies in their device clinic, reviewing programming against current evidence, and building clear post-shock pathways across metropolitan and regional services. Patients who experience a shock should seek urgent advice according to their personalised emergency plan and ensure that the episode is formally interrogated and documented.